Home
HelpTest Code PN23M Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum
Ordering Guidance
This test is the preferred test for patients previously tested for Streptococcus pneumoniae serotypes (as part of follow up testing or part of pre/post vaccine assessment).
The preferred test for patients being evaluated for possible immunodeficiency or for assessment of pneumococcal vaccination response (initial evaluation) is PNTOR / Streptococcus pneumoniae IgG Antibodies, Total, with Reflex, Serum
The preferred test for patients previously tested for total Streptococcus pneumoniae antibodies (as part of follow up testing or part of pre/post vaccine assessment) is PNTO / Streptococcus pneumoniae IgG Antibodies, Total, Serum
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial
Useful For
Assessing the IgG antibody response to active immunization with nonconjugated, 23-valent pneumococcal vaccines
Assessing the IgG antibody response to active immunization with conjugated 13-valent, 15-valent and 20-valent pneumococcal vaccines
Determining the ability of an individual to produce an antibody response to polysaccharide antigens, as part of the evaluation for humoral or combined immunodeficiencies
Method Name
Bead-Based Multiplex Immunoassay
Reporting Name
S. pneumoniae IgG Ab,23 serotypes,SSpecimen Type
SerumSpecimen Minimum Volume
0.4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 21 days | |
| Frozen | 21 days |
Reference Values
Results are reported in mcg/mL
|
Serotype |
Normal value |
|
1 (1) |
≥1.0 |
|
2 (2) |
≥1.0 |
|
3 (3) |
≥1.0 |
|
4 (4) |
≥1.0 |
|
5 (5) |
≥1.0 |
|
8 (8) |
≥1.0 |
|
9N (9) |
≥1.0 |
|
12F (12) |
≥1.0 |
|
14 (14) |
≥1.0 |
|
17F (17) |
≥1.0 |
|
19F (19) |
≥1.0 |
|
20 (20) |
≥1.0 |
|
22F (22) |
≥1.0 |
|
23F (23) |
≥1.0 |
|
6B (26) |
≥1.0 |
|
10A (34) |
≥1.0 |
|
11A (43) |
≥1.0 |
|
7F (51) |
≥1.0 |
|
15B (54) |
≥1.0 |
|
18C (56) |
≥1.0 |
|
19A (57) |
≥1.0 |
|
9V (68) |
≥1.0 |
|
33F (70) |
≥1.0 |
Interpretation
As a general guideline, nonimmunocompromised adults develop IgG antibodies approximately 4 to 6 weeks following nonconjugated vaccination.
Either of the following conditions is consistent with a normal response to Streptococcus pneumonia vaccination:
1. When comparing pre- and post-vaccination samples, antibody concentrations increased by at least 2-fold for
a. >50% of serotypes in children <6 years of age
b. >70% of serotypes for individuals >6 years of age
2. In either a pre- or post-vaccination sample, antibody concentrations >/= 1.0 mcg/mL for
a. >50% of serotypes for children <6 years of age
b. >70% of serotypes for individuals >6 years of age
Clinical Reference
1. Weisberg SS. Pneumococcus. Dis Mon. 2007;53(10):495-502
2. Grabenstein JD and Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine. 2012;30(30):4435-4444
3. Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia. 2022;14(1):5
4. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;2013(1):CD000422
5. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2011;52(10):1241-1247
6. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-117
7. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1174-1181
8. Bonilla RA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205
9. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-S24
Day(s) Performed
Monday through Friday
Report Available
4 to 6 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86317 x 23
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PN23M | S. pneumoniae IgG Ab,23 serotypes,S | 42366-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 620316 | Serotype 1 (1) | 85954-6 |
| 620317 | Serotype 2 (2) | 86039-5 |
| 620318 | Serotype 3 (3) | 86080-9 |
| 620319 | Serotype 4 (4) | 86107-0 |
| 620320 | Serotype 5 (5) | 86130-2 |
| 620321 | Serotype 8 (8) | 86147-6 |
| 620322 | Serotype 9N (9) | 86169-0 |
| 620323 | Serotype 12F (12) | 85977-7 |
| 620324 | Serotype 14 (14) | 85991-8 |
| 620325 | Serotype 17F (17) | 86009-8 |
| 620326 | Serotype 19F (19) | 86024-7 |
| 620327 | Serotype 20 (20) | 86045-2 |
| 620328 | Serotype 22F (22) | 86052-8 |
| 620329 | Serotype 23F (23) | 86064-3 |
| 620330 | Serotype 6B (26) | 27118-9 |
| 620331 | Serotype 10A (34) | 86098-1 |
| 620332 | Serotype 11A (43) | 86122-9 |
| 620333 | Serotype 7F (51) | 25296-5 |
| 620334 | Serotype 15B (54) | 40973-0 |
| 620335 | Serotype 18C (56) | 27395-3 |
| 620336 | Serotype 19A (57) | 40974-8 |
| 620337 | Serotype 9V (68) | 30153-1 |
| 620338 | Serotype 33F (70) | 40969-8 |
| 620404 | Interpretation | 69048-7 |
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.